Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space…

Key Takeaways from the Multiple Sclerosis Pipeline Report Key Takeaways from the Multiple Sclerosis Pipeline Report Request a sample and discover the recent advances in multiple sclerosis treatment drugs @ Multiple Sclerosis Pipeline Report The multiple sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage multiple sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and...

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Nov.13, 2024(GLOBE NEWSWIRE) --Paris, France, November 13, 2024Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of Shares OutstandingTotal number of...

Integra's DuraSeal® Dural Sealant Saves Healthcare Costs According to an…

The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue Integra LifeSciences Holdings Corporation(Nasdaq: IART), a leading global medical technology company, today announced the publication of a new economic study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five...

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver…

PBC program (licensed to Ipsen):Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor) 1on track with expectations; encouraging feedback from healthcare providers and payers in the U.S.UK NICE reimbursement approved and first reimbursed sales in Germany in October 2024Next €26.5M milestone payment by Ipsen pending a third pricing and reimbursement approval in EuropeScientific progress in ACLF to be featured at The Liver...

Alvotech Reports Financial Results for the First Nine Months of 2024

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine months of 2024 increased over four-fold compared to the same period last year, to $128 million, with Q3 product revenues contributing $62 millionLicense and other revenues for the first nine months of 2024 increased by $203 from the same period last year, to $211 million, with Q3...

PHAXIAM Reports Third-Quarter 2024 Financial Information

Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon (France), November 13, 2024, at 5:45 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today reports its financial results for the third quarter of 2024."The third quarter of...

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge…

Saint Herblain (France) and Schlieren (Zurich) ,November 13, 2024 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, andLimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate...

Crossject's ZENEO® Auto-Injector's usability further demonstrated in extreme…

Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack conditions. Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without any handling problem.Study underscores ZENEO® Midazolam's usability in...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 13 November 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...

The board of "Maxima grupė" has had its term extended for another term.

On November 13, 2024, the sole shareholder of MAXIMA GRUPĖ, UAB, UAB "Vilniaus prekyba", made a decision to extend the term of office of the current board for a new four-year term. The board of MAXIMA GRUPĖ, UAB consists of: Manfredas Dargužis, Jolanta Bivainytė, Petar Petrov Pavlov, Lauryna Šaltinė, Agnė Voverė, Arūnas Zimnickas, and Karolina Zygmantaitė. Additional InformationMAXIMA GRUPĖ, UAB manages the retail chains "Maxima" (in the Baltic States), "Stokrotka"…

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a…

177 Lu-PSMA-I&T (INN: lutetium ( 177 Lu) zadavotide guraxetan) versus hormone therapy in patients with metastatic castration-resistant prostate cancer.The ECLIPSE trial demonstrated a statistically significant and clinically meaningful improvement in the median radiographic progression-free survival (rPFS) of patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with up to 6 doses of 200 mCi (7.4 GBq) of...

Genomics Market to Hit USD 66.85 Billion by 2029 with 9.4% CAGR |…

Browse in-depth TOC on "Genomics Market"671 - Tables68 - Figures562 - Pages Browse in-depth TOC on "Genomics Market" 671 - Tables 68 - Figures 562 - Pages Based on offerings,the genomics market is divided into product and service segments. The product segment accounted for the largest share of the genomics market in 2023. This dominance is primarily attributable to the reagents, kits, and other consumables used in sequencing, PCR, and microarray technologies, which represent…

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

Propelling the Next Phase of Innovation in Chronic Wound Management DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare. AMSTERDAM and DUBAI, United Arab Emirates, Nov.13, 2024(GLOBE NEWSWIRE) -- DEBx Medical, an Amsterdam-based pioneering innovator in the field of advanced wound care, announces the successful completion of its second capital investment round led byTVM Capital Healthcare...

ZINZINO AB (PUBL): Zinzino announces Canary Islands as next step in its global…

Market analysis shows that direct selling is a natural way of earning for people seeking an extra income. Digital commerce is growing rapidly and social selling combined with Zinzino's digital toolbox creates favorable conditions for distributors to reach new customers in the Canary Islands. Market analysis shows that direct selling is a natural way of earning for people seeking an extra income. Digital commerce is growing rapidly and social selling combined with Zinzino's digital toolbox...

New Evidence-Based Information from NCCN Offers Tangible and Moral Support for…

"For every patient with cancer who is smoking at diagnosis or anytime during their cancer journey, quitting is absolutely possible. Quitting earlier is better, but any time helps," said Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. Dr. Shields serves as Chair of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Smoking Cessation, which develops evidence-based, expert…

Evaxion receives and appeals delisting determination from Nasdaq, remains…

As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with Nasdaq's equity requirementEvaxion remain committed to ensuring compliance and maintain our Nasdaq listingCOPENHAGEN, Denmark, November 13, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody®…

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on biologic-naïve patients and including evaluation of radiographic progression (IZAR-1), and the other focusing on TNF-IR patients while being the first trial to include risankizumab as an active reference arm (IZAR-2)Program will evaluate sonelokimab for a total of 52 weeks, across IZAR-1...

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative…

"We are thrilled to have licensed several technology platforms from Houston Methodist Hospital and to introduce Continuity Biosciences to the biotechnology and investment communities," said Ramakrishna Venugopalan, Co-Founder & CEO. "There is immense potential at the intersection of biopharmaceuticals and medical technologies, especially in creating combination products that enhance novel therapies. We plan to expand our technology portfolio to provide our partners with…

NaoTrac Robot Pioneers Robotic Neurosurgery in Bolivia with Successful Brain…

Nelson Farfan Espada, Brain Navi's Managing Director for Latin America collaborated closely with the distributor ICERLAB S.R.L. and Hospital Arcoiris to make this groundbreaking initiative a reality. Reflecting on the journey, he shared, "After a challenging yet deeply rewarding process, I believe this program will truly benefit the people of Bolivia. By embracing the latest advancements in precision medicine, we are giving Bolivians access to world-class medical care and the opportunity…

Change in management board

On 13 November 2024, Malene Lunddal Hansen was elected to the management board in Coloplast Finance B.V. replacing Hea Vinskov. Malene Lunddal Hansen is Senior Director for Tax & Compliance in the Coloplast group. The management board in Coloplast Finance B.V. hereafter consists of: Henrik Deneke, Anton Mikkelsen and Malene Lunddal Hansen. Attachment 07_2024_Change_in_management_board

Casino Group: Release of the Strategic Plan Presentation

Bioretec Ltd's business review January-September 2024: Launch of the RemeOs™…

"Innovation Drive Development, Join Hands to Shape the Future" Singclean…

WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space…

Voting Rights and Shares Capital of the Company

Integra's DuraSeal® Dural Sealant Saves Healthcare Costs According to an…

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver…

Alvotech Reports Financial Results for the First Nine Months of 2024

PHAXIAM Reports Third-Quarter 2024 Financial Information

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge…

Crossject's ZENEO® Auto-Injector's usability further demonstrated in extreme…

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

The board of "Maxima grupė" has had its term extended for another term.

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a…

Genomics Market to Hit USD 66.85 Billion by 2029 with 9.4% CAGR |…

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

ZINZINO AB (PUBL): Zinzino announces Canary Islands as next step in its global…

New Evidence-Based Information from NCCN Offers Tangible and Moral Support for…

Evaxion receives and appeals delisting determination from Nasdaq, remains…

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody®…

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative…

NaoTrac Robot Pioneers Robotic Neurosurgery in Bolivia with Successful Brain…

Change in management board